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Objectives: Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) is poorly defined in
cystic fibrosis (CF) patients, and S. aureus detection may be hampered by the presence of small
colony variants (SCVs). We conducted a multicentre survey to determine the prevalence of S. aureus
and MRSA colonization in Belgian CF patients and characterize the phenotype and clonal distribution
of their staphylococcal strains.
Methods: S. aureus isolated from CF patients attending nine CF centres were collected. Oxacillin
resistance was detected by oxacillin agar screen and mecA PCR. Antibiotic susceptibility was tested
by microdilution. MRSA strains were genotyped by PFGE and SCCmec typing and compared with
hospital-associated MRSA strains.
Results: Laboratories used a diversity of sputum culture procedures, many of which appeared
substandard. S. aureus was isolated from 275/627 (44%) CF patients (20% to 72% by centre). The preva-
lence of SCV colonization was 4%, but SCVs were almost exclusively recovered from patients in two
centres performing an SCV search. Phenotypically, 14% of S. aureus isolates were oxacillin-resistant: 79%
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carried mecA and 19% were SCVs lacking mecA. The mean prevalence of ‘true’ MRSA colonization was
5% (0% to 17% by centre). By PFGE typing, 67% of CF-associated MRSA were related to five epidemic
clones widespread in Belgian hospitals.
Conclusions: This first survey of S. aureus colonization in the Belgian CF population indicated a diver-
sity in local prevalence rates and in proportion of oxacillin-resistant and SCV phenotypes, probably
related to variation in bacteriological methods. These findings underscore the need for standard
S. aureus detection methods and MRSA control policies in Belgian CF centres.
Keywords: oxacillin, MRSA, small colony variants
Introduction
Staphylococcus aureus is frequently isolated from bronchial
secretions of cystic fibrosis (CF) patients. It is of particular
concern in paediatric patients, before Pseudomonas aeruginosa
has established its colonization. The prevalence of S. aureus
colonization in the CF population is over 50%, with a maximum
in the 13–17-year-old group.1 Similar prevalence is reported
among adult CF patients in some centres.1,2 Appropriate micro-
biology practices are essential for accurate aetiological diagnosis
in CF lung infections. The use of selective culture media
enhances the recovery of various pathogens from CF sputum.2,3
In the USA, prevalence of S. aureus varies with age and use of
selective culture media. From 40% in infants, the prevalence
reaches a peak of 58% in adolescents to decrease to 38% to
46% in adults with an altered respiratory function, without and
with an S. aureus-specific culture medium respectively.2,3 The
American CF Foundation has published updated recommen-
dations for microbiological workup of CF sputum, and it has
recently been shown that since then, the number of centres in
the USA using appropriate media allowing for S. aureus detec-
tion in CF sputum has increased from 65% to 82%.3,4 In
Belgium, official centres are accredited for CF patient healthcare
since 1999, but microbiological practice by the laboratories sup-
porting these centres is not standardized.
Small colony variant (SCV) phenotypes of S. aureus have
been associated with chronic infection and are a common
finding in CF patients.5,6 SCVs are slowly growing organisms
that exhibit a small, non-pigmented, non-haemolytic colony
morphotype. They are usually dependent on various substrates
(mainly thymidine, haemin and menadione) supplementation for
growth and are more resistant to antibiotics such as aminoglyco-
sides and co-trimoxazole.5,6 Epidemiologial studies in CF
patients have documented a 10% prevalence of SCV S. aureus
strains from two centres in the USA and a 33% prevalence in
one centre in Germany.7,8
In several regions of the world, infection with methicillin-
resistant S. aureus (MRSA) is reported with increasing fre-
quency in children and is no longer confined to patients with
specific risks factors.9,10 In Europe and the USA, the proportion
of MRSA among S. aureus recovered from CF patients varies
from 8% to 23%.11 – 14 The clinical impact of MRSA carriage
remains uncertain in CF patients. In a retrospective case–control
study, children with MRSA infection received more courses of
intravenous antibiotic therapy and had poorer growth than
patients without MRSA. Chest X-rays were worse at baseline in
the MRSA-infected patients, and no effect of this infection
could be shown on lung function.15 Long-term persistence of
S. aureus in CF lungs has been demonstrated.16,17 In adult CF
patients, MRSA colonization has been shown to be transient in
some cases or persist for years in other patients.18,19 The present
study was undertaken to determine the prevalence and micro-
biological characteristics of colonization with methicillin-
susceptible S. aureus (MSSA) and MRSA in Belgian CF
patients receiving care in specialized treatment centres and one
rehabilitation facility.
Patients and methods
Study design
We conducted a 7 month multicentre prospective survey from June
until December 2001. Eleven specialized CF care facilities were
invited to participate. Nine were included, among which were six of
the eight accredited CF centres, two other hospitals caring for CF
patients and one rehabilitation centre. At the time of study, the
National CF Registry counted 788 patients who attended a CF centre
three or four times a year. Sputum samples are usually collected for
microbiological analysis on each visit. All participating laboratories
were asked to refer S. aureus isolates from consecutive CF patients
attending each clinic to the coordinating laboratory. The isolates
were sent on trypticase soy agar transport medium, except for the
rehabilitation centre, which was invited to send primary sputum cul-
tures on mannitol salt agar medium (Becton Dickinson,
Cockeysville, MD, USA). One isolate of S. aureus was collected per
patient, unless different phenotypes (morphological aspect or anti-
biotic resistance profile) were recovered on the same or consecutive
sputum samples. Participating laboratories also registered the total
number of sputum cultures performed in CF patients and the number
of CF patients for which at least one respiratory culture was obtained
during the study period. They were asked to describe their standard
operating procedures for CF sputum microbiological testing.
Characterization of S. aureus strains
Identification and oxacillin susceptibility testing. S. aureus iso-
lates were referred to the National Reference Laboratory for
Staphylococci, where identification was confirmed by coagulase test
in human plasma and latex agglutination test (Pastorex Staph-Plus,
Sanofi Pasteur). SCVs of S. aureus were defined as small greyish or
non-pigmented colonies, non-haemolytic and slowly growing on
blood agar media.20 Susceptibility to oxacillin was tested according
to the CLSI (formerly the NCCLS) on oxacillin screen agar (BBL,
Becton Dickinson) with 6 mg/L oxacillin for 24 h at 358C.21
Identification of S. aureus and oxacillin resistance was confirmed by
triplex PCR, allowing for the detection of fragments of 16S rRNA
(Staphylococcus spp. specific region), nuc (coding for S. aureus
thermonuclease) and mecA (coding for the PBP2a) genes.22
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Antimicrobial susceptibility testing. MICs were determined using
broth microdilution testing according to the CLSI for eight anti-
biotics: oxacillin, vancomycin, teicoplanin, amikacin, gentamicin,
ciprofloxacin, co-trimoxazole and linezolid.21 Mueller–Hinton
(MH) broth was used for MIC determination of S. aureus isolates
with normal colony phenotype, and MH broth supplemented with
2% NaCl was used for oxacillin susceptibility testing. Isolates with
an SCV phenotype were tested in MH broth supplemented with
thymidine (100 mg/L), haemin (1 mg/L) and menadione (1 mg/L)
with a prolonged incubation of 48 h at 358C. Endpoints were read
after 18, 24 and 48 h of incubation.
Molecular typing. MRSA strains, defined as S. aureus isolates
harbouring the mecA gene, were genotyped by PFGE of genomic
macrorestriction fragments (using SmaI).23 Patterns were normalized
and analysed with the BioNumerics software (Applied Maths,
Kortrijk, Belgium), in comparison with a database of .1000 nor-
malized patterns from a collection of MRSA isolates from hospital
surveys in Belgium and other European countries during the period
1987–2001. Pattern matching was based on the Dice coefficient for
similarity analysis. The unweighted pair group method using arith-
metic average (UPGMA) was used to establish the dendrogram
grouping of PFGE types. PFGE profiles of CF patients isolates were
compared with 12 epidemic clones previously described from the
national surveillance of Belgian hospitals.23 PFGE profiles were
classified according to the published criteria.24 MRSA were further
characterized by determining the type of SCCmec cassette using a
multiplex PCR.25
Statistical analysis
Analyses were performed using SPSS version 13.0 and EpiInfo
version 3.3.2. We used the Pearson x2 and Fisher’s exact test for
expected count less than 5. The Mann–Whitney test was used for
median comparison (non-Gaussian distributions).
Results
S. aureus prevalence and characteristics
During the study, 627 CF patients had at least one sputum
culture performed in one of the participating centres (80% of all
CF patients in the national registry). The review of laboratory
procedures for processing CF sputum for culture indicated that
all but three laboratories were plating CF sputum on S. aureus-
specific media: mannitol salt agar from different manufacturers
was used in five centres (Oxoid in Centres 5, 6 and 7, Becton
Dickinson in Centre 4 and Difco in Centre 9). An enriched
Gram-positive-specific medium containing colistin and aztreo-
nam was used by one laboratory. S. aureus was isolated from
275 (44%) patients with a median age of 17 years (ranging from
3 months to 49 years). The prevalence of S. aureus colonization
ranged from 20% to 72% by centre (Figure 1) (heterogeneity
x2 ¼ 42 and 43, P, 0.000001). In the centre where S. aureus
was isolated in 72% of the CF patients, the median age was 22
years, whereas it was 13 and 18 years in the two centres with
the lowest prevalence of S. aureus (20% and 28%, respectively)
(Table 1). All isolates were referred to the coordinating labora-
tory, except for 33 isolates from Centre 5, which were not
available.
A total of 424 strains from 242 patients were received by the
reference laboratory. Phenotypic and genotypic identification of
S. aureus was confirmed for these 424 strains, and the mecA
status was determined in order to exclude duplicate isolates from
the same patient. These were defined as follow: (i) strains with
identical colony morphology, i.e. normal phenotype or SCV
phenotype and (ii) strains with identical mecA status, i.e. MRSA
or MSSA.
A total of 268 S. aureus strains were included for further
study. A single strain was analysed from 219 patients and
multiple strains with distinct morpho/resistance type (49 strains)
were characterized from 23 patients. The coagulase test on
human plasma was positive in 261/268 (97.4%) strains and latex
agglutination in 265 (98.9%) strains. Species identification was
confirmed by PCR detection of the nuc gene in 268 (100%)
isolates and the 16S rRNA gene in 265 (98.9%). Identification
of the three remaining strains, which presented an SCV pheno-
type, was confirmed by sequence determination of the 16S
rRNA gene amplified with a different DNA polymerase.
Small colony variants
SCV S. aureus isolates were recovered from 25/594 (4.2%) CF
patients, with wide variation between the centres (Table 1).
Only four centres found SCV isolates, but only three were per-
forming a systematic search for SCVs in CF patients’ sputa. The
majority of SCVs were isolated in a single laboratory which pro-
cessed specimens from two centres. These SCVs were recovered
on mannitol salt agar from Becton Dickinson in Centre 4 and
Difco in Centre 9. The median age of patients carrying SCV
S. aureus strains was 21 years (ranging from 9 to 38 years),
when compared with 16 years (ranging from 0 to 49 years) for
patients with normal phenotype S. aureus (P, 0.001).
Antibiotic susceptibility
MICs were determined for 259 (96.6%) strains. MIC results
indicated that all isolates were susceptible to vancomycin, teico-
planin and linezolid, 91% were susceptible to gentamicin, 89%
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Figure 1. S. aureus and MRSA prevalence (rate of S. aureus and MRSA in
CF patients who had at least one sputum sample collected during the study
period) by CF centre (n ¼ 9) and national mean prevalence. Comparison of
S. aureus prevalence: prevalence varied widely among the centres: *P,
0.05; **P, 0.01; *** P, 0.0001.
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to amikacin and co-trimoxazole and 58% to ciprofloxacin
(Table 2).
On the basis of MIC testing, 35 (14%) of the isolates were
oxacillin-resistant. Among these, 11% (27 strains) were MRSA
and 3% (8 strains, including 7 SCVs) did not carry mecA but
had oxacillin MIC 4 mg/L. On the other hand, 20% of MRSA
isolates did not grow on oxacillin screen agar: this was seen for
3/5 MRSA isolates with SCV phenotype when compared with 3/
24 of those with normal phenotype (P, 0.05). SCV strains
were more likely to be resistant to co-trimoxazole (88%) and
oxacillin (48%) than strains with normal phenotype (1.7% and
11%, respectively; P, 0.00001).
‘True’ MRSA were recovered from 5% of the CF patients
included in the study (Figure 1). The MRSA prevalence by
centre varied significantly (heterogeneity x2 ¼ 21.62, P ¼
0.003), with no MRSA recovered from CF patients in three
centres and 17% in one centre. Similarly, the proportion of
MRSA among S. aureus was significantly different in the nine
centres (crude OR by the maximum likelihood method: 0.321;
(95% CI: 0.131–0.746; P ¼ 0.026). This difference almost lost
statistical significance once adjusted for age (,19 years old and
19 years old). Adjusted OR was 0.415 (0.165–0.997) (P ¼
0.045), indicating that age was a confounding factor. The
median age of MRSA-colonized patients was significantly
higher than that of MSSA-colonized patients (22 versus 17
years, respectively; P, 0.005). Moreover, there was a positive
correlation between the median age of the patients in a given
centre and the proportion of MRSA recovered from these
patients (r2 ¼ 0.611, P ¼ 0.02).
The majority of CF patients colonized with MRSA
(67%) were carrying a strain belonging to one of the epidemic
clones that are disseminated in Belgian hospitals (Clones A,
B, C, D, J). Nine patients carried Clone A MRSA, four
Clone B2 and three Clone C3, whereas Clones D and J were
recovered from one patient each (Figure 2). Patients colonized
with Clone A were older (median age of 30 years) than the
patients harbouring Group B strains (median age 10.5 years;
P ¼ 0.003). There were four clusters of two patients carrying the
same strain (two pairs of patients cared for in the same centre
and two from distinct centres). SCCmec types were correlated
with the PFGE types and the gentamicin resistance profile
(Figure 2).
Table 1. Prevalence of S. aureus, MRSA and S. aureus SCV colonization by centre
Centre
Mean sputum samples
per patient
Number of CF patients
with culture
Median age
(range in years)
Number of CF patients (%) with
S. aureusa MRSA SCV
1 3.8 20 13 (7–19) 4 (20) 0 0
2 3.4 116 18 (4–40) 33 (28) 6 (5) 0
3 3.6 37 16 (5–39) 11 (30) 0 0
4 5.7 82 15 (5–35) 34 (42) 2 (2) 7 (10)
5 3.1 131 13 (8–27) 23 þ 33b (43) 2 (NA) 0 (NA)
6 3.7 81 20 (6–49) 41 (51) 5 (6) 2 (3)
7 2.2 91 15 (0–34) 48 (53) 3 (3) 4 (4)
8 4.3 16 07 (2–11) 10 (63) 0 0
9 5.2 53 22 (10–40) 38 (72) 9 (17) 12 (23)
National 3.75 594 þ 33b 17 (0–49) 242 þ 33b (44) 27 (5) 25 (4)
NA, not available.
aAll S. aureus, including MRSA and SCV.
bThirty-three patients whose strains were not available for study.
Table 2. MICs for 259 S. aureus isolates from 242 CF patients (patients with both normal and SCV phenotype or MRSA and MSSA had
two strains tested) determined by broth microdilution methods
Antibiotic
Number of isolates with MIC value (mg/L)
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 .64
Oxacillin 44 49 60 43 18 10 3 4 3 3 4 18
Vancomycin 16 70 108 53 12 0 0 0 0 0 0 0
Teicoplanin 189 38 15 10 1 6 0 0 0 0 0 0
Gentamicin 97 53 45 29 10 0 1 0 0 0 5 19
Amikacin 0 2 3 8 34 78 60 36 11 15 4 8
Ciprofloxacin 47 30 27 20 27 22 15 22 12 15 9 13
Co-trimoxazole 133 57 26 8 5 1 2 2 2 1 1 20
Linezolid 14 27 100 94 22 1 0 0 0 0 0 0
One strain of MSSA with normal phenotype was not tested for co-trimoxazole and linezolid.
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Discussion
The mean prevalence of S. aureus carriage (44%) among pae-
diatric and adult CF patients in Belgium was slightly lower than
that reported for Europe.1 Although we expected to find more
paediatric than adult patients colonized with S. aureus, no
association was observed between the median age of the patients
and the prevalence of S. aureus in a given centre. There was evi-
dence for bias towards underdetection of S. aureus in the centres
which did not use specific S. aureus selective isolation medium
as recommended by the CF Foundation.3 Microbiological
workup of sputum from CF patients constitutes a challenge,
because specific media must be used to enhance recovery of
slow growing or variant organisms like S. aureus SCVs. In
patients colonized with P. aeruginosa, this pathogen can over-
grow S. aureus and thereby interfere with detection if selective
media are not used. Investigators have shown that S. aureus
DNA could be identified in CF sputum in patients whose culture
was negative.26 Furthermore, the frequency of sputum sampling
per patient could also influence the S. aureus recovery, as the
organism may be intermittently isolated. However, we did not
find a correlation between the number of sputum samples per
patient and the S. aureus carriage rate.
SCV S. aureus have been associated with persistent infections
and are typically recovered from CF patients who are recurrently
treated with co-trimoxazole or other antibiotics.8,20,27 SCV
S. aureus prevalence in this study was lower than that previously
reported from CF patients in other countries.7,8 However, this is
probably due to underdetection, as only three centres were
actively searching for SCVs in respiratory specimens from CF
patients. Most centres failed to detect any SCVs, presumably
because they were not using an appropriate technique. SCVs
may be more common in older patients, as they have had a per-
sistent infection for a longer period of time and have received
more antibiotic courses. Nevertheless, one study found an SCV
phenotype in 32% of the S. aureus from CF children.28
The MRSA prevalence observed in Belgian CF patients was
low (5%), but showed wide variation by centre. This can be
partly explained by differences in sensitivity of the methods
used for S. aureus detection. Oxacillin agar screen was not a
suitable medium for detection of SCV MRSA. As shown by
others, PCR detection of mecA remains the most sensitive diag-
nostic tool for SCV MRSA detection.29 However, the proportion
of MRSA among S. aureus isolates recovered from CF patients
also varied greatly by centre. It is likely that the variations in
MRSA prevalence rates were related to the incidence of noso-
comial acquisition in the hospital where the CF centre is located
and to local infection control practices. Another risk factor for
MRSA colonization was age. Older patients were at an increased
risk of carrying MRSA. Older patients are more likely to have
spent more time in hospital, thereby increasing their probability
of becoming colonized by hospital-acquired MRSA. The finding
that most MRSA isolated from the CF population in this study
belonged to predominant Belgian nosocomial clones is consist-
ent with this source of contamination, as proposed by other
investigators.19 Additional evidence to support this hypothesis is
the observation that older MRSA-colonized patients harboured
preferentially gentamicin-resistant Clone A1-SCCmec I strains,
PFGE 
group SCCmec
Gentamicin 
resistance 
Patient 
age 
(years) Phenotype
A20 IVA S 30 N
A20 IV S 29 N
A1* IA R 27 N
A1* IA R 27 SCV
A1 IA R 39 N
A1 IA R 22 N
A1** IA R 38 SCV
A1** IA R 38 N
A1 IA R 39 N
A26*** IA R 32 N
A25 IA I 19 N
K1*** ND ND 32 N
K1** IA R 38 SCV
Sporadic I R 22 N
Sporadic IVA S 19 N
Sporadic III S 31 N
C3 IV S 2 N
C3 IVA S 17 N
C3 IV S 2 N
Sporadic I R 27 SCV
Sporadic ND ND 20 N
D4 I R 22 N
Sporadic I R 24 N
Sporadic IA R 37 N
B2**** IV S 17 N
B2**** IV S 17 SCV
B2 IV S 0 N
B2 IV S 13 N
B2 IV S 8 N
Sporadic IVA S 22 SCV
J3 IV S 18 
Sporadic ND S 40 N
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Figure 2. PFGE profiles of 32 MRSA strains from 27 CF patients, similarity percentage (Dice coefficient) between the profiles and group, type and subtype
according to SCCmec type, gentamicin resistance, patient age and phenotype. ND, not determined; R, resistant; I, intermediate; S, susceptible; N, normal
phenotype; SCV, SCV phenotype. *, **, *** and **** indicate MRSA isolates from the same patients, respectively, when patients were carrying both normal
and SCV phenotypes (*, ** and ****) and in ** and ***, distinct MRSA clones.
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which were found in the majority of Belgian hospitals during
the 1980s and early 1990s, whereas younger CF patients typi-
cally carried gentamicin-susceptible Clone B2-SCCmec IV
MRSA, which has gradually emerged in the late 1990s.24
However, the distribution of these epidemic clones was different
in CF patients when compared with the general population.
Group A1-SCCmec I strains accounted for 19% of all MRSA in
CF patients, whereas this clone represented 3% of the Belgian
MRSA during the same period.24 PFGE type A1 MRSA prob-
ably persisted for many years in the CF patients’ lungs, as has
been shown for S. aureus in CF patients’ lungs.16
Multiple antibiotic-resistant S. aureus was not a common
occurrence in this study. Oxacillin resistance was due to mecA
in 11% of the S. aureus strains of the CF patients and to
other non-investigated mechanisms in 3% of the cases.
Oxacillin resistance was high among SCV strains, which had
not been reported in other studies.8,28 The strains were tested
in non-standard conditions using a supplemented MH broth,
providing the nutrient supplementation that their auxotrophism
requires. No standard technique exists for S. aureus SCV sus-
ceptibility testing and, as enriched media are used, revertants
might be tested in some cases. However, in S. aureus isolated
from CF patients, selection of mutants with novel resistance
mechanisms has been linked to the expression of a modified
PBP3 with a decreased affinity for oxacillin in one patient30
and for macrolides by ribosomal modification due to mutations
in the 23S rRNA gene.31
In conclusion, we observed a similar prevalence of MRSA
and MSSA colonization in CF patients treated in specialized
centres in Belgium to that reported elsewhere in Europe and
North America. It is likely that true prevalence was underesti-
mated because of the use of suboptimal laboratory methods. In
particular, S. aureus SCVs were not sought nor detected in
many laboratories. Further studies would be necessary to ascer-
tain their incidence and study their clinical impact on CF
patients. Our findings underline the need for improvement and
harmonization of microbiological procedures for diagnosis of
lung infection in CF patient care centres in Belgium.
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